Aktiesnakken — November 2010
-
Endvidere
fortsættes drøftelsen om samarbejde med de globale diagnostiske selskaber, som er interesserede i at
markedsføre nyreskademarkøren -
som et vigtigt produkt i porteføljen af tests til deres egne analyseapparater.
Flere af de store globale selskaber har modtaget The NGAL Tes -
Test for at udføre intern validering og tilpasning af
testen til deres respektive fuldautomatiske testapparater.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind